Milgram's public statements, juxtaposed with the DEA's restrictive actions, paint a picture of an agency at odds with itself-one that claims to prioritize public health while simultaneously obstructing access to innovative treatments that could save lives. As the legal and public pressure mounts, the DEA may be forced to reconsider its approach, leading to a new era of drug policy in America
Read MoreMagdalena Biosciences, a joint venture formed by Jaguar and Filament Health, is focused on developing novel prescription psychoactive plant-based medicines for various mental health indications
Read MoreNew patent issued for core rare disease target indication for crofelemer
Napo has approximately 230 patents issued and pending
Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025
Read More
Successful IPO that raised $6.4 million on July 31, 2024, without issuing any warrants, occurred after the end of the second quarter and is not reflected in reported financials
Conversion of all reported outstanding preferred shares and debt into equity occurred as of the date of the IPO and is not reflected in the reported financials
After IPO and preferred shares and debt conversion share issuances, there are 20.85 million common shares outstanding, with 1.86 million common shares available to be traded
Underwriter lockups limit potential for deposit or trading of remaining 18.99 million common shares
As of the date of the IPO, Company had no debt, cash runway for lead program OST-HER2 into mid-2025
Net Loss and Earnings per Diluted Share of $10.6 million and $17.48
Adjusted EBITDA was a $2.9 million loss, a $2.8 million improvement versus second quarter of 2023
The Company expects to generate between $2.0 million and $2.5 million in revenue in the third quarter of 2024
Read MoreSubmitted FDA 510(k) Application and Passed FDA Administrative Review for the mBôs TKA System
Secured Initial Strategic Multicenter Clinical Trial Collaboration with Shalby Limited
Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time
Read MoreCompany provides nearly 80% statewide comprehensive insurance coverage in Utah under contract with providers such as Medicare, Select Health, Medicaid, and Blue Cross Blue Shield
Reimbursement from insurance payors increased 163.7% sequentially and is expected to increase as a percentage of total revenue going forward
Reimbursements from insurance payors totaled $126,325 in first half of 2024 as compared to $0 during the first half of 2023
Read More
